🇪🇺 recombinant subunit Herpes zoster vaccine in European Union

EMA authorised recombinant subunit Herpes zoster vaccine on 21 March 2018

Marketing authorisation

EMA — authorised 21 March 2018

  • Application: EMEA/H/C/004336
  • Marketing authorisation holder: GlaxoSmithKline Biologicals S.A.
  • Local brand name: Shingrix
  • Indication: Shingrix is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in: adults 50 years of age or older; adults 18 years of age or older at increased risk of HZ. The use of Shingrix should be in accordance with official recommendations.
  • Status: approved

Read official source →

recombinant subunit Herpes zoster vaccine in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Immunology / Infectious Disease approved in European Union

Frequently asked questions

Is recombinant subunit Herpes zoster vaccine approved in European Union?

Yes. EMA authorised it on 21 March 2018.

Who is the marketing authorisation holder for recombinant subunit Herpes zoster vaccine in European Union?

GlaxoSmithKline Biologicals S.A. holds the EU marketing authorisation.